Tonix Pharmaceuticals Holding Corp. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

SALE AND PURCHASE OF COMMON STOCK (Details Narrative)

SALE AND PURCHASE OF COMMON STOCK (Details Narrative) - USD ($)											2 Months Ended	12 Months Ended
	Dec. 31, 2025	Dec. 29, 2025	Jun. 11, 2025	Jun. 11, 2025	Jul. 31, 2024	Jul. 09, 2024	Jun. 27, 2024	Jun. 12, 2024	Apr. 02, 2024	Mar. 28, 2024	Mar. 12, 2026	Dec. 31, 2025	Dec. 31, 2024	Nov. 30, 2025	Sep. 30, 2024	May 22, 2024
Class of Stock [Line Items]
Stock offering expenses												$ 8,750,000	$ 7,238,000
Net proceeds	$ 8,600,000
Shares repurchased												847,903
Price per share												$ 16.19
Cost of repurchased shares												$ 13,760,000
2024 Share Repurchase Program [Member]
Class of Stock [Line Items]
Share repurchase authorized amount														$ 35,000,000	$ 10,000,000
Shares repurchased												847,903
Cost of repurchased shares												$ 13,760,000
2024 Share Repurchase Program [Member] \| Minimum [Member]
Class of Stock [Line Items]
Price per share												$ 9.98
2024 Share Repurchase Program [Member] \| Maximum [Member]
Class of Stock [Line Items]
Price per share												$ 20.47
Common Warrants [Member]
Class of Stock [Line Items]
Number of shares for common warrants									2,172
Exercise price									$ 1,056.00							$ 1,056.00
Termination date									Apr. 01, 2029
Common Warrants Series A [Member]
Class of Stock [Line Items]
Number of shares for common warrants									2,782
Termination date									Apr. 01, 2029
Common Warrants Series B [Member]
Class of Stock [Line Items]
Number of shares for common warrants									2,782
Termination date									Apr. 01, 2025
Common Warrants Series C [Member]
Class of Stock [Line Items]
Number of shares for common warrants									10,884
Termination date									Apr. 01, 2026
Period of trading days after FDA acceptance of NDA for warrant expiration									10 days
Common Warrants Series D [Member]
Class of Stock [Line Items]
Number of shares for common warrants									10,884
Termination date									Apr. 01, 2029
Purchase Agreement [Member]
Class of Stock [Line Items]
Number of shares issued		615,025				33,936	28,339	11,995
Price per share		$ 16.26				$ 57.00	$ 57.00	$ 106.50
Stock offering expenses		$ 1,500,000				$ 500,000	$ 600,000	$ 600,000
Placement agent fees		1,200,000				300,000	300,000	300,000
Net proceeds		$ 18,500,000				$ 3,500,000	$ 3,400,000	$ 3,400,000
Purchase Agreement [Member] \| 2025 Lincoln Park Transaction [Member]
Class of Stock [Line Items]
Number of shares issued				48,708
Net proceeds				$ 1,800,000
Common stock purchase			$ 75,000,000
Purchase Agreement [Member] \| Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Number of shares for common warrants		615,025				37,032	42,282	25,682
Price per share		$ 16.259				$ 56.99	$ 56.99	$ 106.40
2025 Sales Agreement [Member] \| Alliance Global Partners [Member]
Class of Stock [Line Items]
Number of shares issued												4,100,000
Net proceeds												$ 104,200,000
Offering price per agreement			$ 400,000,000
Commission to agent			3.00%
2025 Sales Agreement [Member] \| Alliance Global Partners [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Number of shares issued											600,000
Net proceeds											$ 8,600,000
2024 Sales Agreement [Member] \| Alliance Global Partners [Member]
Class of Stock [Line Items]
Number of shares issued												4,500,000	4,200,000
Net proceeds												$ 112,900,000	$ 128,400,000
Offering price per agreement					$ 250,000,000
Commission to agent					3.00%
Sales Agreement [Member]
Class of Stock [Line Items]
Number of shares issued										3,365
Price per share										$ 960.00
Stock offering expenses										$ 500,000
Placement agent fees										300,000
Net proceeds										$ 3,900,000
Offset to proceeds from issuance of warrants													$ 3,000,000
Sales Agreement [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Number of shares issued											600,000
Net proceeds											$ 8,600,000
Sales Agreement [Member] \| Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Number of shares for common warrants										1,219
Price per share										$ 959.68
Sales Agreement [Member] \| Common Warrants Series E [Member]
Class of Stock [Line Items]
Number of shares for common warrants										4,584
Exercise price										$ 1,056.00
Warrants and Rights Outstanding, Term										5 years 6 months